NASDAQ · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · LARGE CAP
Celldex Therapeutics, Inc. CLDX
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$1.5M
▼ 78.0% vs FY2024
EPS · FY25
$-3.90
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-40.6%
Net margin · FY25
-16748.0%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 1.5M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
The company lost 16748 cents on every revenue dollar this year.
Per share
USD -3.90
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-40.6%
Return on equity, FY2025
ROE
Operating margin-18599.8%
Net margin-16748.0%
Return on assets-37.6%
Each USD of equity lost 41 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−26.9% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−13.1%
−26.9%
−11.9%
−20.3%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.07B
Shares outstanding, FY2025
Change, 5 years+68.0%
Change, 10 years—
The share count grew 68% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 583.0M
total assets, end of FY2025
Total assetsUSD 583.0M
EquityUSD 527.2M
CashUSD 28.9M
Current ratio10.49×
Equity funds 90% of total assets.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.3
−0.2
−0.2
−0.1
−0.1
−0.1
−0.1
−0.2
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
EBITDA $B
−0.3
−0.2
−0.2
−0.1
−0.1
−0.1
−0.1
−0.2
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
·
−0.0
−0.0
·
−0.0
−0.0
·
·
·
0.0
0.0
·
·
−0.0
Net income $B
−0.3
−0.2
−0.1
−0.1
−0.1
−0.1
−0.1
−0.2
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
EPS, diluted $
−3.90
−2.45
−2.92
−2.40
−1.64
−2.02
−3.51
−14.48
−10.86
−18.99
−1.31
−1.32
−1.02
−1.02
−1.13
−0.08
−1.84
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−40.6
−26.8
−37.4
−30.1
−22.4
−39.4
−46.7
−83.9
−37.1
−46.3
−50.7
−44.4
−39.2
−71.9
−62.2
−3.4
−49.5
Shares out B
0.07
0.07
0.06
0.05
0.05
0.04
0.02
0.01
0.01
0.12
0.10
0.09
0.09
0.06
0.04
0.03
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
49 of 49
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed